Replimune Group (REPL) stock

Cancer immunotherapies , market cap $1.9B

Oncolytic immunotherapies for cancer

Worth $1.9B

$23.28

+4.58%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Average

In its industry

#49of 281

Biotech

Checks firing

9of 14

Trending up

From 52-week high

-0.6%

under its best in a year

REPL's Quality Score was unchanged on Tue, Nov 10, at 10.

Follow REPL's trial news. Pro members can get an alert when Replimune Group files news, and see its trials, share raises, and its CEO's filings.

Get an alert when REPL files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2030“The primary endpoint, expected to readout in 2030, is overall survival, and key secondary”Trial data · SEC filing · Aug 14

Why is REPL up?

Up 4.6% today, while its biotech peers are down 1.4%; no story names it yet.

Rose 78% since Oct 27

Up 78% from Oct 27 to Nov 10.

Its Oct 28 results: second-quarter net loss narrowed to $57.1M, from $83.1M a year before. It rose 23% on Oct 28.

Sources: Price history, Nov 10, 2026; Company release, Oct 28, 2026

1 more reason, free with an account →3 more reasons why REPL rose 78% since Oct 27, from its filings, with the timeline and its peers, for Pro members.

Key facts on REPL

Key facts on REPL
The chart	Stronger than 99% of stocks above every average
Latest filing	8-K, Oct 28 Reported its quarterly results

1 more reason behind REPL's 10, free with an account →4 more reasons behind REPL's 10, for Pro members.

REPL in the news

TodayNo story names it yet.

REPL catalysts

Coming up

After its last 4 reports it closed +5.9% on average, higher 2 of 4 times.

5 past catalysts since 2026, with sizes and sources, for Pro members.

What's next for REPL, and how long its cash lasts

Next step the company has named

2030“The primary endpoint, expected to readout in 2030, is overall survival, and key secondary”Trial data · SEC filing · Aug 14

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaPhase 2/3 · Recruiting · 280 people · main data estimated Jan 2030 · NCT06581406

7 more trials, 1 with data due this year, 41 filings, for Pro members.

Cash runway

The company says its cash lasts into the fourth quarter of 2026 (8-K, Nov 6, 2025).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Aug 14, 2026)
At-the-market share sales program (S-3ASR, filed Aug 14, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Director Kapil Dhingra sold 21,500 shares on Nov 2. 13 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Sushil Patel buys or sells

For Pro members: every trade, and Sushil Patel’s 18 filings and quotes.

Get an alert when REPL files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why REPL scores 10

Averagefor quality, not price, 9 of 14 chart checks firingWhat the Quality Score means

Well above its recent run. REPL scores 10 today, against a median of 6 over its last 20 recorded sessions.

+9Chart checks 9 of 14 firing right now, one point each
+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high

Run-up adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Growth, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on REPL and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:45 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when REPL's Quality Score turns up

A free account. No card.

How REPL ranks in Biotech

REPL is #49 of 281 by Quality Score.

How REPL ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	RCUSArcus Biosciences		Open for its score
	REGNRegeneron Pharmaceuticals		Open for its score
	RGENRepligen		Open for its score
	RGNXREGENXBIO		Open for its score
49	REPLReplimune	9/14	10

When does REPL report earnings, and what happens after?

Expected to report Wed Feb 3, before the open (in 85 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What REPL reported on Oct 28, 2026

The quarter

A loss of $0.54 a share, from $0.90.

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

REPL's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value: $1.9B; today
Free cash flow: -$246M; last 12 months

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on REPL: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

+5.8%-3.7%-1.4%+23.1%

Feb 3Jun 29Aug 14Oct 28

Reported	When	Gap	Reaction	5 days
Oct 28, 2026Before open	Before open	-0.7%	+23.1%	+58.2%
Aug 14, 2026Before open	Before open	0.0%	-1.4%	-7.5%
Jun 29, 2026Before open	Before open	-2.0%	-3.7%	-1.4%
Feb 3, 2026Before open	Before open	+0.8%	+5.8%	+11.5%

REPL closed higher after 2 of its last 4 reports.

REPL has 9 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on REPL, and all 14 on every stock.Get in free →

REPL RSI today: 82.8, above its 50-day and 200-day averages

Not scored

RSI 82.8, MACD above signal, above both averages. Not scored.13 readings

The deep dive on REPL

What it does and how it makes money2 findingsFor Pro members2 findings on what REPL does and how it makes money, for Pro members
Where it stands3 findingsIt spent $246M more than its operations brought in over the four quarters to Sep 30, 2026, after capital spending.Cash flow statements to Sep 30, 2026, filed Oct 28, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades REPL, for Pro members

6 more findings on REPL, each with its source, for Pro members.

REPL share count over time

Shares: 14.4% more than a year ago (to Sep 30).

Shares of REPL outstanding, as filed
Shares outstanding	As of
94.8M	Oct 23, 2026
94.2M	Aug 11, 2026
83.9M	Jun 25, 2026
82.6M	Jan 30, 2026

Offerings, shelves, and splits of REPL, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Aug 14, 2026
Priced a sale of shares	Aug 10, 2026
Registered shares for a later sale (S-3)	May 23, 2025
Raised $90M in a sale of shares, about 5% of its market value	Nov 26, 2024

REPL insider trades

8 insiders sold $2M across 13 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellJoseph P. Slattery$113KDirectorat $21.80 on Nov 9, filed today

SellJoseph P. SlatteryDirector$113Kat $21.80 on Nov 9, filed today

All 13 insider filings on REPL from the last six months, for Pro members.

REPL's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Sushil PatelChief Executive Officer · 3 trades
Emily Luisa HillChief Financial Officer · 3 trades
Christopher SarchiChief Commercial Officer · 4 trades
Konstantinos XynosChief Medical Officer · 3 trades
Andrew SchwendenmanChief Accounting Officer · 2 trades
Kapil DhingraDirector · 2 trades
Joseph P. SlatteryDirector · 1 trade
Philip Astley-SparkeDirector · 1 trade

See insider trades by person

Which ETFs hold REPL?

In ETFs: REPL is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Replimune Group

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

465 employeesWoburn, MAreplimune.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on REPL and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move REPL's score: 7 things
6 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaynowJoseph P. Slattery sold REPL$113K at $21.80, filed Nov 10

Alerts are optional.

See REPL's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: REPL's Quality Score is 10 (Average), #49 of 281 in Biotech. Insiders sold $2M in the last 6 months (Form 4).

What does REPL's Quality Score say?

REPL scores 10 today, which Breakaway calls Average. It is #49 of 281 in Biotech by Quality Score, with 9 of 14 chart checks firing. Up 78% from Oct 27 to Nov 10. Shares: 14.4% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is REPL's Quality Score?

REPL scores 10 today, which Breakaway calls Average (6 to 10). That is #49 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind REPL's 10.

Are insiders buying REPL?

8 insiders sold $2M across 13 filings in the last 6 months. No open-⁠market buys on record. The newest is Joseph P. Slattery, Director, who sold $113K on Nov 9. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.